A team of investigators sought to determine the prevalence of proton pump inhibitor-partial response gastroesophageal reflux disease in patients with systemic sclerosis.
The performance of 5 core set measure in ACR-CRISS in recent trials was explored, and their ability to discern the active medication group from placebo in patients with diffuse cutaneous systemic sclerosis (dcSSc), was assessed.
Close monitoring of patients with systemic sclerosis-associated interstitial lung disease and awareness of the variable course of progression is highly important in considering when to initiate treatment.
Study authors analyzed the effects of nintedanib on changes in forced vital capacity and other measures of progression in systemic sclerosis-associated interstitial lung disease.